NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and identifying patients most likely t ...

SELLAS Life Sciences Group, Inc. has announced promising preclinical results for SLS009, a selective CDK9 inhibitor, in treating TP53 mutated Acute Myeloid Leukemia (AML) cells, which typically have ...

BUFFALO, NY- October 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.” As highlighted in this ...

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and ...

1.5-year clinical outcomes in patients with triple-mutated AML who were positive and negative for MRD before allo-HSCT. This paper explores the clinical outcomes of allogeneic hematopoietic stem cell ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

Good day, everyone, and welcome to the Syndax Conference Call to Discuss the FDA approval of Revuforj in Relapsed/Refractory NPM1 Mutated AML. Today's call is being recorded. [Operator Instructions] ...

Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML? The following represents disclosure information provided by the author of this manuscript. All relationships are ...